Founded in July 2005, Porton Pharma Solutions Ltd. (Stock abbreviation: Porton Share; Stock code: 300363) is a leading pharmaceutical CDMO (Contract Development Manufacture Organization) in China. From the early stage of development, Porton has provided global pharmaceutical companies and new drug R&D (Research and Development) institutions with customized R&D.
To Build the World’s leading Pharma Solutions Platform
Synergizing with Small Molecule API and Intermediates CDMO Services
Offering World-Class Gene/Cell Therapeutics Development and Manufacturing Services
Porton is proud to have earned the trust of some of the world’s leading and most innovative pharmaceutical companies and many biotechnology companies across the US, EU and Asia.Business Cooperation
Porton Announces Acquisition of Yuyang Pharmaceutical to Expand Its Manufacturing Capacity
Porton Reports Strong Half-Year Results
CfPC Announces Program of 2021 Pharmaceutical Crystallization Summit(Reproduced)